secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2025-06-02T23:59:59+00:00
Accession:  0001193125-25-133273
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Trevi Therapeutics terminates ATM prospectus; past sales $14.6M gross
---------------------------------------------------------------------

- On June 2, 2025, Trevi terminated the August 15, 2023 ATM prospectus with Leerink Partners.
- Sales Agreement remains in effect; no sales permitted until a new prospectus is filed.
- As of March 31, 2025, Trevi sold 4,498,065 shares for gross proceeds of ~$14.6M.
- No shares issued or sold under the Sales Agreement after March 31, 2025.
- Commissions and fees on past sales totaled approximately $0.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000119312525133273/0001193125-25-133273-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000119312525133273/d911843d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-133273

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer